Safety, Tolerability, Pharmacokinetics and Efficacy of EYP001a in Patients With Nonalcoholic Steatohepatitis (NASH)

Overview

The purpose of this study is to assess the effects of EYP001a (Vonafexor) with respect to safety, tolerability, pharmacokinetics and on markers of liver inflammation in patients with NASH

Full Title of Study: “A Phase 2a, Randomized, Double-Blind, Multicenter, Placebo-Controlled Study to Assess the Safety, Tolerability, Pharmacokinetics, and Efficacy of EYP001a in Patients With Nonalcoholic Steatohepatitis”

Study Type

  • Study Type: Interventional
  • Study Design
    • Allocation: Randomized
    • Intervention Model: Parallel Assignment
    • Primary Purpose: Treatment
    • Masking: Triple (Participant, Care Provider, Investigator)
  • Study Primary Completion Date: June 16, 2021

Detailed Description

This is a 2-part, randomized, double-blind, multicenter, placebo-controlled study to evaluate the safety and efficacy of Vonafexor in patients with NASH who likely have stage F2 to F3 fibrosis at approximately 50 global clinical sites. Overall, approximately 114 eligible patients will be enrolled: 24 patients in Part A (Safety Run-in Cohort), followed by 90 patients in Part B. In Part A, 24 patients will be randomized on Day 1 to 1 of 4 parallel treatment groups: 100 mg Vonafexor twice daily (BID), 200 mg Vonafexor once daily (QD), 400 mg Vonafexor QD, or placebo BID. In Part B, 90 patients will be randomized on Day 1 to 1 of 3 parallel treatment groups: 100 mg Vonafexor QD, 200 mg Vonafexor QD, or placebo QD.

Interventions

  • Drug: Vonafexor
    • Oral tablets
  • Other: Placebo
    • Oral tablets

Arms, Groups and Cohorts

  • Experimental: Vonafexor 100 mg BID
    • Oral dose twice daily for 12 weeks (84 days)
  • Experimental: Vonafexor 200 mg QD
    • Oral dose once daily for 12 weeks (84 days)
  • Experimental: Vonafexor 400 mg QD
    • Oral dose once daily for 12 weeks (84 days)
  • Placebo Comparator: Placebo
    • Oral dose twice daily for 12 weeks (84 days)
  • Experimental: Vonafexor 100 mg QD
    • Oral dose once daily for 12 weeks (84 days)

Clinical Trial Outcome Measures

Primary Measures

  • Analysis of Absolute Change From Baseline in Percentage of Fat in the Liver as Assessed by Magnetic Resonance Imaging – Proton Density Fat Fraction (MRI-PDFF)
    • Time Frame: 12 weeks
    • The liver fat percentage was assessed by MRI-PDFF, which is an established method that enables the quantification of fat content in the liver; the value of liver fat is expressed in percentage and ranges from 0 to 100% with higher values representing higher liver fat level.

Secondary Measures

  • Analysis of Change From Baseline in Glomerular Filtration rate_Part B
    • Time Frame: 12 weeks
  • Analysis of Percent Change (Relative) From Baseline in Percentage of Fat in the Liver as Assessed by Magnetic Resonance Imaging – Proton Density Fat Fraction (MRI-PDFF)
    • Time Frame: 12 weeks
    • The liver fat percentage was assessed by MRI-PDFF, which is an established method that enables the quantification of fat content in the liver; the value of liver fat is expressed in percentage and ranges from 0 to 100% with higher values representing higher liver fat level.
  • Analysis of Change From Baseline in Corrected T1 (CT1)
    • Time Frame: 12 weeks
  • Analysis of Change From Baseline in Alanine Aminotransferase (ALT)
    • Time Frame: 12 weeks
  • Analysis of Change From Baseline in Gamma Glutamyltranspeptidase (GT)
    • Time Frame: 12 weeks
  • Analysis of Change From Baseline in Body Weight
    • Time Frame: 12 weeks
  • Analysis of Change From Baseline in Waist Circumference
    • Time Frame: 12 weeks
  • Analysis of Change From Baseline in Waist to Hip ratio_Part B
    • Time Frame: 12 weeks
  • Analysis of Change From Baseline in Glomerular Filtration rate_Part A
    • Time Frame: 12 weeks
    • For Part A, as per ICH, analysis were performed as defined in the SAP: data from the 3 vonafexor treatment groups were pooled and compared with the placebo group.

Participating in This Clinical Trial

Inclusion Criteria

  • Written informed consent – Suspected diagnosis of NASH, evidenced by elevated alanine aminotransferase (ALT), liver stiffness compatible with F2 or F3 fibrosis and Liver Fat Content (LFC) ≥10% as measured by MRI – Women of childbearing potential and male patients with female partners must agree to use a dual method of contraception Exclusion Criteria:

  • Evidence of worsening liver injury – Previous diagnosis of other forms of non-NASH liver disease – Use of Vitamin E, glitazones, glucagon-like Peptide-1 receptor agonists, ursodeoxycholic acid, or obeticholic acid within 90 days prior to screening – History of cirrhosis or liver decompensation – Known history of alcohol abuse or daily heavy alcohol consumption – Pregnant or breastfeeding women – Type 1 diabetes mellitus and uncontrolled type 2 diabetes mellitus – Patients with contraindications to MRI imaging

Gender Eligibility: All

Minimum Age: 18 Years

Maximum Age: 75 Years

Are Healthy Volunteers Accepted: No

Investigator Details

  • Lead Sponsor
    • Enyo Pharma
  • Provider of Information About this Clinical Study
    • Sponsor
  • Overall Official(s)
    • Harrison Stephen, MD, Principal Investigator, Pinnacle Clinical Research

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.